Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings

Detalhes bibliográficos
Autor(a) principal: Santana, Wanessa
Data de Publicação: 2021
Outros Autores: de Oliveira, Simone S. C., Ramos, Mariana H., Santos, André L. S., Dolabella, Silvio S., Souto, Eliana B., Severino, Patrícia, Jain, Sona
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/74070
Resumo: Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (invitro, invivo), drug repurposing and clinical research.
id RCAP_6501344d0aa6f0a0e56b8962846d04db
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/74070
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findingsLeishmaniasisNew targetsPre-clinicalClinicalDrug repurposingScience & TechnologyLeishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (invitro, invivo), drug repurposing and clinical research.This research was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico for the Scientific grants (CNPq 301964/2019-0 Chamada No. 06/2019, Chamada CNPq No. 01/2019) and Portuguese Science and Technology Foundation, Ministry of Science and Education (FCT/MEC) through the sponsorship of the project M-ERA-NET-0004/2015-PAIRED (strategic fund), co-financed by FEDER, under the Partnership Agreement PT2020. We would like to thank Tiago Branquinho Oliveira for the help provided in drawing Figure 3.info:eu-repo/semantics/publishedVersionWiley-BlackwellUniversidade do MinhoSantana, Wanessade Oliveira, Simone S. C.Ramos, Mariana H.Santos, André L. S.Dolabella, Silvio S.Souto, Eliana B.Severino, PatríciaJain, Sona2021-092021-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/74070engSantana, Wanessa; de Oliveira, Simone S. C.; Ramos, Mariana H.; Santos, André L. S.; Dolabella, Silvio S.; Souto, Eliana; Severino, Patrícia; Jain, Sona, Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings. Chemistry & Biodiversity, 18(9), e2100336, 20211612-187210.1002/cbdv.20210033634369662https://onlinelibrary.wiley.com/doi/10.1002/cbdv.202100336info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:44:16Zoai:repositorium.sdum.uminho.pt:1822/74070Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:41:56.058664Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
title Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
spellingShingle Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
Santana, Wanessa
Leishmaniasis
New targets
Pre-clinical
Clinical
Drug repurposing
Science & Technology
title_short Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
title_full Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
title_fullStr Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
title_full_unstemmed Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
title_sort Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings
author Santana, Wanessa
author_facet Santana, Wanessa
de Oliveira, Simone S. C.
Ramos, Mariana H.
Santos, André L. S.
Dolabella, Silvio S.
Souto, Eliana B.
Severino, Patrícia
Jain, Sona
author_role author
author2 de Oliveira, Simone S. C.
Ramos, Mariana H.
Santos, André L. S.
Dolabella, Silvio S.
Souto, Eliana B.
Severino, Patrícia
Jain, Sona
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Santana, Wanessa
de Oliveira, Simone S. C.
Ramos, Mariana H.
Santos, André L. S.
Dolabella, Silvio S.
Souto, Eliana B.
Severino, Patrícia
Jain, Sona
dc.subject.por.fl_str_mv Leishmaniasis
New targets
Pre-clinical
Clinical
Drug repurposing
Science & Technology
topic Leishmaniasis
New targets
Pre-clinical
Clinical
Drug repurposing
Science & Technology
description Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (invitro, invivo), drug repurposing and clinical research.
publishDate 2021
dc.date.none.fl_str_mv 2021-09
2021-09-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/74070
url http://hdl.handle.net/1822/74070
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Santana, Wanessa; de Oliveira, Simone S. C.; Ramos, Mariana H.; Santos, André L. S.; Dolabella, Silvio S.; Souto, Eliana; Severino, Patrícia; Jain, Sona, Exploring innovative Leishmaniasis treatment: drug targets from pre-clinical to clinical findings. Chemistry & Biodiversity, 18(9), e2100336, 2021
1612-1872
10.1002/cbdv.202100336
34369662
https://onlinelibrary.wiley.com/doi/10.1002/cbdv.202100336
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley-Blackwell
publisher.none.fl_str_mv Wiley-Blackwell
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132970333765632

Registros relacionados